The main findings of this study were the subsequent: (1) the combination of the biomarkers demonstrated a good predictive ability for patients at risk for AKI occurrence; (2) combined results according to widely used cut-offs of 0.3 for [TIMP-2] × [IGFBP7] and 0.5 for PCT allowed risk stratification of the population for AKI development within 48 h; (3) A double-marker positivity, defined by the concomitant positivity of both biomarkers was also significantly associated with mortality within 7 days in septic subgroup and with AKD at 7 days in non-septic patients. This evidence concerns the gene IGFBP7 and acute kidney injury.